Home
Kristin Greve-Isdahl Mohn's picture

Kristin Greve-Isdahl Mohn

Associate Professor
  • E-mailkristin.mohn@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. npj Vaccines.
  • Show author(s) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 pages.
  • Show author(s) (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Frontiers in Immunology. 11 pages.
  • Show author(s) (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Frontiers in Public Health. 13 pages.
  • Show author(s) (2023). Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 10 pages.
  • Show author(s) (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
  • Show author(s) (2023). Cost-Effectiveness of Vaccination of Older Adults with an MF59<sup>®</sup>-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden. Vaccines. 21 pages.
  • Show author(s) (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. Viruses. 1-11.
  • Show author(s) (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
  • Show author(s) (2022). Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines. 10 pages.
  • Show author(s) (2022). Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. Viruses.
  • Show author(s) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 pages.
  • Show author(s) (2022). Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chemical Biology.
  • Show author(s) (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 pages.
  • Show author(s) (2021). Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Frontiers in Immunology. 16 pages.
  • Show author(s) (2021). Neutrophil count predicts outcome in hospitalized COVID-19 patients. Results from the NOR-Solidarity trial. Journal of Internal Medicine. 241-243.
  • Show author(s) (2021). Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study. Infectious Diseases. 1-12.
  • Show author(s) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Show author(s) (2021). Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scandinavian Journal of Immunology. 1-9.
  • Show author(s) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 pages.
  • Show author(s) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Show author(s) (2020). Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. Journal of Infectious Diseases. 97-108.
  • Show author(s) (2020). Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. Journal of Infectious Diseases. 356-366.
  • Show author(s) (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
  • Show author(s) (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
  • Show author(s) (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
  • Show author(s) (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
  • Show author(s) (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
  • Show author(s) (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
  • Show author(s) (2016). Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis. Influenza and Other Respiratory Viruses. 192-204.
  • Show author(s) (2016). Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 191-198.
  • Show author(s) (2015). The expression of B & T cell activation markers in children’s tonsils following live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics. 1663-1672.
  • Show author(s) (2015). The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. Journal of Infectious Diseases. 80-90.
  • Show author(s) (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
  • Show author(s) (2015). Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLOS ONE. 16 pages.
  • Show author(s) (2014). The Influence of Tonsillectomy on Total Serum Antibody Levels. Scandinavian Journal of Immunology. 377-379.
  • Show author(s) (2014). Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. The Lancet Respiratory Medicine. 395-404.
  • Show author(s) (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 266-273.
Lecture
  • Show author(s) (2022). Pandemihåndtering i Norge.
  • Show author(s) (2022). Influensa og vaksiner.
  • Show author(s) (2021). klinisk bilde ved Covid sykdom, hvorfor er det så ulikt?
  • Show author(s) (2021). Vaksiner, smarte, små stikk!
  • Show author(s) (2021). Covid-19 Immunitet og vaksinerespons.
  • Show author(s) (2018). Influensavaksine, hva er det, og hvorfor bør vi ta det?
  • Show author(s) (2017). Virale epidemier, historiske og fremtidige trusler.
  • Show author(s) (2017). Vaksinemotstand på liv og død?
Popular scientific lecture
  • Show author(s) (2015). Ytringsfrihet.
Academic lecture
  • Show author(s) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
Book review
  • Show author(s) (2015). Dyptgående og informativt om vaksiner Bok anmeldelse: Vaksiner En forbannet velsignelse av Bjarne Bjorvatn. Tidsskrift for Den norske legeforening.
Popular scientific article
  • Show author(s) (2018). Pandemivaksinen i 2009-en forberedelse til neste influensapandemi. Best practices.
Feature article
  • Show author(s) (2018). Få en influensafri jul! Bergens Tidende.
  • Show author(s) (2017). Nok tro og folelser na. Bergens Tidende.
  • Show author(s) (2017). Gravide – se opp for fake news! Bergens Tidende.
  • Show author(s) (2015). Sølje Bergman er farligere for barn enn vaksiner. Bergens Tidende.
Letter to the editor
  • Show author(s) (2023). SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity. Journal of Infection. 346-349.
Doctoral dissertation
  • Show author(s) (2016). Immune response to influenza after vaccination and infection.
Interview
  • Show author(s) (2022). Ny vaksinestudie: – Svært viktig.
  • Show author(s) (2020). Harvard-professor om coronvaviruset: Tror over 40 prosent vil bli smittet .
  • Show author(s) (2019). Dette appa­ratet kan på 15 minutter finne ut om du har influ­ensa.
  • Show author(s) (2014). Behandling med Tamiflu reduserte mortaliteten under Pandemien i 2009.
Documentary
  • Show author(s) (2013). Målet er en livsvarig supervaksine mot influensa.
  • Show author(s) (2013). Forskning på ny influensa vaksine for barn.
Programme participation
  • Show author(s) (2021). UiB Innsikt: Bergens vaksineforskning – i går, i dag og i morgen.
Academic literature review
  • Show author(s) (2020). COVID-19 and venous thromboembolism - prophylaxis and treatment. Tidsskrift for Den norske legeforening. 6 pages.
  • Show author(s) (2018). Clinical expectations for better influenza virus vaccines - perspectives from the young investigators' point of view. Vaccines. 1-16.
  • Show author(s) (2017). Immune responses after live attenuated influenza vaccination . Human Vaccines & Immunotherapeutics. 571-578.
Article in business/trade/industry journal
  • Show author(s) (2018). Immunrespons etter levende svekket influensavksine. Best practices.

More information in national current research information system (CRIStin)